Sur180 Therapeutics is a female-led business that focuses on novel ways to treating gynecological diseases.
Sur180 Therapeutics has raised $2.4M in total funding. The most recent round was Grant. The last funding was announced in July 2025.
Sur180 Therapeutics's investors include National Institutes of Health, The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
Sur180 Therapeutics is headquartered in Mcallen, United States.
Sur180 Therapeutics is a female-led business that focuses on novel ways to treating gynecological diseases.
Sur180 Therapeutics is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Sur180 Therapeutics — Funding & Investors." VCBacked, July 9, 2025, https://www.vcbacked.co/company/sur180-therapeutics. Accessed July 20, 2026.
VCBacked. (2025). Sur180 Therapeutics — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/sur180-therapeutics
{{cite web |title=Sur180 Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/sur180-therapeutics |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated